ATE328081T1 - Antiangiogene eigenschaften von vascostatin und fragmenten und varianten davon - Google Patents

Antiangiogene eigenschaften von vascostatin und fragmenten und varianten davon

Info

Publication number
ATE328081T1
ATE328081T1 AT01962422T AT01962422T ATE328081T1 AT E328081 T1 ATE328081 T1 AT E328081T1 AT 01962422 T AT01962422 T AT 01962422T AT 01962422 T AT01962422 T AT 01962422T AT E328081 T1 ATE328081 T1 AT E328081T1
Authority
AT
Austria
Prior art keywords
vascostatin
fragments
variants
antiangiogenic properties
properties
Prior art date
Application number
AT01962422T
Other languages
German (de)
English (en)
Inventor
Raghuram Kalluri
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE328081T1 publication Critical patent/ATE328081T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
AT01962422T 2000-03-29 2001-03-28 Antiangiogene eigenschaften von vascostatin und fragmenten und varianten davon ATE328081T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19287100P 2000-03-29 2000-03-29

Publications (1)

Publication Number Publication Date
ATE328081T1 true ATE328081T1 (de) 2006-06-15

Family

ID=22711364

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01962422T ATE328081T1 (de) 2000-03-29 2001-03-28 Antiangiogene eigenschaften von vascostatin und fragmenten und varianten davon

Country Status (8)

Country Link
EP (1) EP1268798B1 (enExample)
JP (1) JP2003528609A (enExample)
AT (1) ATE328081T1 (enExample)
AU (1) AU8727401A (enExample)
CA (1) CA2403515A1 (enExample)
DE (1) DE60120131T2 (enExample)
NZ (1) NZ521567A (enExample)
WO (1) WO2001073025A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525595A (ja) * 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
CN1455682A (zh) 2001-01-05 2003-11-12 百疗医株式会社 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
EP3842452A1 (en) 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Scaffold proteins and therapeutic nanoconjugates based on nidogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides

Also Published As

Publication number Publication date
CA2403515A1 (en) 2001-10-04
WO2001073025A2 (en) 2001-10-04
WO2001073025A3 (en) 2002-06-27
DE60120131T2 (de) 2007-01-04
NZ521567A (en) 2004-04-30
EP1268798B1 (en) 2006-05-31
DE60120131D1 (de) 2006-07-06
JP2003528609A (ja) 2003-09-30
AU8727401A (en) 2001-10-08
EP1268798A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DE60238206D1 (de) Frequenz- und amplitudenapodisierung von wandlern
DE50012863D1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE60212600D1 (de) Audiocodierung und decodierung
EP1578771A4 (en) REMODELING AND GLYCOKON JUGATION OF PEPTIDES
DE60326749D1 (de) Speichern und abrufen von informationen
EP1451293A4 (en) NEW SULFURYLASE LUCIFERASE FUSION PROTEINS AND TEMPERATURE STABLE SULFURYLASE
DE60217432D1 (de) Verwendungen von Kohlenstofffasern
DE60122196D1 (de) Synergistische antioxidans-kombination von delta tocols und polyphenolen
DK1305301T3 (da) Alpha-acyl- og alpha-heteroatomsubstituerede benzenacetamidglucokinase-aktivatorer
FI20010523A0 (fi) Soolien, geelien ja niiden seosten käsittely
DE50112013D1 (de) Deodorantien und antiperspirantien
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE60126814D1 (de) Inhalation von stickoxid
ATE277045T1 (de) Salze von bicyclischen, n-acylierten imidazo-3- aminen und imidazo-5-aminen
NO20030882D0 (no) Glasskeramikkmasse og anvendelse derav
DE60102122D1 (de) Zusammensetzung von Poly-1-Butenharz und dessen Verwendung
DE60124418D1 (de) Assoziation von calpaine und inhibitoren von reaktive-sauerstoff frei radikalen
DE60120131D1 (de) Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon
DE60115467D1 (de) Herstellungsverfahren und eigenschaften von styrol-butadien random-copolymer/poly(arylenether) zusammensetzungen
DE60121146D1 (de) Anti-angiogenic properties of matin and of fragments or variants thereof
DE60007360T2 (de) Amorphe modifikation von torasemid
DE69927626D1 (de) Ausführung von Permutationen
EP1071333A4 (en) INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENS
EP1432448A4 (en) NOVEL HKID-1-ASSOCIATED PROTEIN FAMILY MOLECULES AND USES THEREOF
DE69930014D1 (de) Wirksame verarbeitung von mehrfachverbindungsverkehr

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268798

Country of ref document: EP

REN Ceased due to non-payment of the annual fee